Background {#Sec1}
==========

*Escherichia coli* (*E.coli*) are a common member of microflora of the gastrointestinal tract of animals and humans. Pathogenic *E. coli* associated with gastrointestinal disorders have been divided into eight pathotypes based on their virulence profiles: enteropathogenic *E. coli* (EPEC); enterohaemorrhagic *E. coli* (EHEC); enterotoxigenic *E. coli* (ETEC); enteroinvasive *E. coli* (EIEC); enteroaggregative *E. coli* (EAEC); diffusely adherent *E. coli* (DAEC); adherent invasive *E. coli* (AIEC); and shiga toxin-producing enteroaggregative *E. coli* (STEC) \[[@CR1]\]. Among them, ETEC infects both humans and several species of farm animals such as pigs. In humans, ETEC is the main cause of bacterial diarrhea in adults and children in developing countries and also a leading cause of traveler's diarrhea \[[@CR2], [@CR3]\]. In pigs, enteric diseases due to strains of ETEC are the most commonly occurring form of colibacillosis including neonatal diarrhoea and postweaning diarrhoea (PWD), which result in significant economic losses due to mortality, morbidity, reduced growth rate and cost of medication \[[@CR4]\].

Quinolones, which trap DNA gyrase or topoisomerase IV to form reversible drug enzyme DNA cleavage complexes, to cause bacteriostasis, have a high bioavailability, good tissue penetration, long half-lives, high efficacy, and low incidence of adverse effects. Because of these characteristics, they are widely used against several respiratory and gastrointestinal infections in both humans and animals \[[@CR5], [@CR6]\]. The antimicrobial treatment of traveler's diarrhea has changed over the years because of the increasing resistance of ETEC to common antibiotics. So far, fluoroquinolones have been shown to be an effective therapy for ETEC traveler's diarrhea \[[@CR7], [@CR8]\]. Danofloxacin (DANO), a third generation fluoroquinolone antimicrobial drug with rapid bactericidal activity, is often employed to treat colibacillosis in swine via oral or intramuscular administration \[[@CR9], [@CR10]\]. However, their extensive use has also serious non-desirable impacts and represents a public health danger. For example, it may stimulate the emergence of zoonotic quinolone-resistant *E.coli* in the food-producing animals, which can ultimately be transmitted to the human by direct contact or through the food chain \[[@CR11], [@CR12]\]. Plasmid-mediated fluoroquinolone resistance genes (qnrS and aac (6′)-Ib-cr) are detected in both patients and pigs in Shandong, China, and these resistance genes can be transmitted horizontally \[[@CR13]\].

Improper use of antibiotics results in severe bacterial resistance. Breakpoints are routinely used in the clinical laboratory setting to guide clinical decision making. A combination of MIC values, pharmacokinetic/pharmacodynamic relationship and clinical outcome data are needed to set breakpoints \[[@CR14]\]. However, this kind of data needed for breakpoint determination is so difficult and expensive to generate. Epidemiological cutoff values (ECVs) are the useful tools for laboratories conducting susceptibility testing and for clinicians treating infections. Those tools also offer alternative ways for monitoring the emergence of drug resistance in any given bacterial species \[[@CR14]\]. ECVs establishment using the CLSI method must include MIC distributions (≥ 100 MIC results per species and Antibacterial agent) from multiple (≥ 3) independent laboratories \[[@CR15], [@CR16]\]. Previous studies demonstrated that a statistical method was a professional and scientific method which has been adopted by the CLSI as a standard method for ECV determination \[[@CR17], [@CR18]\]. Pharmacodynamic cutoff (CO~PD~) is associated with clinical efficacy, as both WT values and PK/PD data are used to setting CO~PD~ without clinical cutoff values \[[@CR19]\]. The CO~PD~ was defined as the MIC at which the probability of target attainment (PTA) was ≥90% \[[@CR20]\]. Monte Carlo simulation has been employed to assess the probability of attaining the desired AUC:MIC ratio, and it provides a means by which probability outcomes, such as achieving the PK/PD target, can be attained without the rigor, time, and expense of clinical trials \[[@CR21], [@CR22]\].

The purposes of the present study were (i) to develop ECV of DANO against *E.coli* using a statistical method and (ii) to establish DANO CO~PD~ for *E.coli* based on Monte Carlo simulation.

Results {#Sec2}
=======

Isolates {#Sec3}
--------

From July 2014 to March 2017, a total of 861 *E.coli* isolates were identified from 864 rectal/cloacal swabs of pigs. Isolates were collected from Heilongjiang (*n* = 296), Jilin (*n* = 151), Liaoning (*n* = 238), Henan (*n* = 97), Shandong (*n* = 30), Hubei (*n* = 20), and Yunnan (*n* = 29) provinces of China.

Antibacterial susceptibility testing {#Sec4}
------------------------------------

As shown in the primitive DANO MIC distribution in Fig. [1](#Fig1){ref-type="fig"}, MICs for DANO against 1233 *E.coli* isolates (861 isolated, 372 donated) were in the range of 0.008 to 128 μg/mL. The percentages at each MIC (0.008, 0.016, 0.03, 0.06, 0.03, 0.25, 0.5, 1, 2, 4, 8, 16, 32, 64 and 128 μg/mL) were 0.73, 3.97, 2.35, 0.73, 3.16, 7.38, 13.22, 10.62, 6.16, 5.43, 7.54, 12.98, 7.62, 8.76 and 9.33%. The MIC~50~ and MIC~90~ were 4 and 128 μg/mL, respectively.Fig. 1Primary MIC distribution of danofloxacin against 1233 *E.coli* isolates

Epidemiological cut-off values {#Sec5}
------------------------------

The MIC distribution (0.008-128 μg/mL) for DANO was statistically consistent with a normal distribution because the skewness (− 0.321) and kurtosis (− 0.731) were negative. As the normal (Gaussian) distribution is widely accepted, non-linear regression curve fitting of cumulative log~2~ MIC data was selected as the preferred method for determining the means and standard deviations of MIC distributions. The procedure involved fitting the initial subset and generating estimates for the number of strains in the subset, the mean and the standard deviation (in log). This procedure was repeated by adding to the previous subset each successive column to create the next subset, and repeating the curve-fitting until it was clear that there was a subset where the absolute difference between the true and estimated number of isolates was a minimum. As shown in Table [1](#Tab1){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}, the seven subsets examined showed that the subset 'MIC = 8 μg/ mL' gave the minimum difference. As a result, the ECV was defined as 8 μg/mL.Table 1Optimum non-linear least squares regression fitting of pooled MICs (mg/mL) for danafloxacin and *E.coli*SubsetNumber of isolatesMean MIC (log~2~)Standard deviation (log~2~)fittedTRUEEst.Diff.ASEEst./ASE95%CIbEst.ASEEst./ASE95%CI^a^Est.ASEEst./ASE95%CI^b^≤1281233.001417.00184.00106.6013.291185 to 16502.220.544.121.046 to 3.3944.630.4211.013.711 to 5.544≤641118.001293.00175.00108.5011.921054 to 15321.640.552.950.4138 to 2.8564.270.439.903.324 to 5.224≤321010.001174.00164.00114.3010.27919.5 to 14291.070.591.81−0.2443 to 2.3853.930.468.642.918 to 4.947≤16916.001040.00124.00113.909.13782.2 to 12980.420.600.70−0.9379 to 1.7803.530.477.532.471 to 4.594≤8b756.00829.8073.8063.5613.06683.2 to 976.3−0.630.36−1.75−1.469 to 0.20082.810.338.542.051 to 3.569≤4663.00786.90123.9093.928.38564.8 to 1009−0.850.51−1.68−2.041 to 0.34762.660.416.431.679 to 3.634≤2596.00980.00384.00353.302.77115.5 to 1844−0.011.47−0.01−3.611 to 3.5903.120.793.951.184 to 5.052Est., non linear regression estimate of value; Diff., estimate of N minus true N; ASE, asymptotic standard error; Est./ASE, estimate divided by asymptotic standard error^a^95% CI of estimate of value^b^This subset gave the smallest difference between the estimate and true number of isolates in the subsetFig. 2Iterative non-linear regression curve fitting with increasing subsets. X axis = Log~2~ MIC, Y axis = numbers of isolates. Numbers below each graph are the values for the true number of isolates included in the dataset (True n), the non-linear regression estimate (Estimated n) and the difference between these two values of n (Difference). O = observed numbers; solid line = fitted curve

In vitro time-kill studies {#Sec6}
--------------------------

As presented in Fig. [3](#Fig3){ref-type="fig"}, the concentrations (1/4 MIC and 1/2 MIC) below the MIC of DANO can hardly inhibited the growth of *E. coli* JLP95. Similarly, the bacteriostatic effects of 1MIC and 2MIC of DANO are not obvious. However, the antibacterial or bactericidal effects are gradually enhanced when DANO concentrations were at least 4 times higher than MIC. Therefore, the in vitro time-kill test shows that efficacy of DANO against *E.coli* is concentration dependent.Fig. 3The in vitro time killing curve of danofloxacin against *E.coli*

Pharmacokinetic characteristics of DANO in plasma {#Sec7}
-------------------------------------------------

There are no adverse reactions after intramuscular injection of DANO. The concentration of plasma DANO was decreased below LOQ after 72 h. The concentration-time curves are presented in Fig. [4](#Fig4){ref-type="fig"}. According to MAICE, the plasma data were best fitted to a two-compartmental PK model for all six pigs. Pharmacokinetic parameters are shown in Table [2](#Tab2){ref-type="table"}, the time to reach to maximum drug concentration (T~max~), the peak drug concentration (C~max~), and the area under the curve by 24 h (AUC~0--24~) were 0.97 ± 0.08 h, 0.76 ± 0.08 μg/mL, and 5.25 ± 1.35 h·μg/ml, respectively.Fig. 4Concentration-time plot of plasma danofloxacin data at 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 h after i.m. administration at a dose rate of 2.5 mg/kg in pigs. Values are means±SD (*n* = 6)Table 2PK parameters for danofloxacin in pig plasma after i.m. administration at a dose of 2.5 mg/kg (*n* = 6)PK parameterUnitMean ± SDAμg/mL2.09 ± 1.46Bμg/mL0.41 ± 0.17α1/h0.81 ± 0.41β1/h0.10 ± 0.02K~a~1/h2.00 ± 0.51K~10~1/h0.25 ± 0.08K~12~1/h0.32 ± 0.20K~21~1/h0.34 ± 0.23T~1/2Ka~h0.37 ± 0.09T~1/2α~h1.07 ± 0.60T~1/2β~h7.28 ± 1.10AUCh\*μg/mL5.25 ± 1.35T~max~h0.97 ± 0.08C~max~μg/mL0.76 ± 0.08CLL/h7.75 ± 1.74V~c~liter/kg2.28 ± 0.39V~p~liter/kg2.16 ± 0.86V~ss~liter/kg4.17 ± 0.76A and B: Y-axis intercept terms; α: distribution rate constant; β: elimination rate constant; K~a~: absorption rate constant; K~10~: central compartment elimination rate constant; K~12~: rate constant from central to peripheral compartment; K~21~: rate constant from peripheral to central compartment; T~1/2Ka~: absorption half-life of the drug; T~1/2α~: distribution half-life of the drug; T~1/2β~: elimination half-life of the drug; AUC: area under the curve of plasma concentration-time; T~max~: the time point of maximum plasma concentration of the drug; C~max~: the maximum plasma concentration; CL: body clearance; V~c~: volume of distribution in the central compartment; V~p~: volume of distribution; V~ss~: volume of distribution at steady state

Monte Carlo analysis {#Sec8}
--------------------

Results of a 10,000- Monte Carlo simulation for DANO based on MIC and AUC~0--24~, the probability of achieving various AUC: MIC ratios at breakpoints of 0.03 μg/mL are presented in Fig. [5](#Fig5){ref-type="fig"}. The red bars represent the number of simulated with AUC: MIC ratios \< 125, whereas the gray bars represent with AUC: MIC ratios of ≥125. The probability of DANO attaining an AUC: MIC ratio of at least 125 is 92.25%. Therefore, the CO~PD~ was defined at 0.03 μg/mL. The following statistical parameters describe the DANO AUC: MIC probability distribution: mean 188.84, median 188.86, SD 44.91, variance 2017.05, skewness - 0.024, kurtosis 3.03, coeff. of variability 0.24, minimum range 10.42, maximum range 345.06, and mean std. error 0.45.Fig. 5Results of a 10,000-iteration Monte Carlo simulation for danofloxacin based on MIC and AUC~0--24~. The red bars represent the number of simulated with AUC: MIC ratios \< 125, whereas the gray bars represent with AUC: MIC ratios of ≥ 125. The probability of danofloxacin attaining an AUC: MIC ratio of at least 125 is 92.25%. Therefore, the CO~PD~ was defined as 0.03 μg/mL

Discussion {#Sec9}
==========

DANO is a fluoroquinolone antibacterial drug that was developed specifically for veterinary use \[[@CR23]\]. However, the resistant *E.coli* isolates are emerging quickly with the use of these drugs \[[@CR24]\]. A total of 1737 *E. coli* isolates collected from the United States, Canada, Belgium, France, Germany, Italy, the Netherlands, Spain, the United Kingdom, Japan, and South Africa showed a high degree of susceptibility to DANO, more than 99.3% of the *E. coli* isolates with an MIC of ≤1.0 μg/ml \[[@CR25]\]. While, in our study, 50.82% of the *E. coli* isolates (*n* = 1233) with MIC \>1.0 μg/ml for DANO, which indicated that temporal and geographic differences could be frequently found on the prevalence of resistance.

Susceptibility breakpoints of quinolones and fluoroquinolones (ciprofloxacin, levofloxacin, cinoxacin, enoxacin, gatifloxacin, gemifloxacin, grepafloxacin, lomefloxacin, nalidixic acid, norfloxacin, ofloxacin, and fleroxacin) for *Enterobacteriaceae* have been established. CLSI \[[@CR16]\] recommendations for testing human pathogens against fluoroquinolone, but few guidelines are available for the interpretation of veterinary MIC data. ECV can be used as the most sensitive measurement of the emergence of strains with decreased susceptibility to a given compound when compared with the WT population. These non-WT strains may exhibit one or more acquired resistance mechanisms \[[@CR26]\]. Several methods have been reported for determination of ECVs. For instance, Arendrup et al. estimated ECVs as 2-fold dilution steps higher than the MIC~50~ \[[@CR27]\], Rodriguez-Tudela et al. estimated them as 2-fold dilutions above the modal MIC \[[@CR28]\], and Kronvall and Turnidge et al. calculated ECVs by statistical methods \[[@CR17], [@CR18]\]. We used nonlinear least squares regression analysis reported in the CLSI methodology to determine ECVs. Finally, the ECV of *E.coli* for DANO was defined as 8 μg/mL according to the preliminary MIC distribution in our study.

Several studies have established pharmacokinetic data for DANO in a number of farm animal species, including cattle, sheep, goat, chicken and pig \[[@CR23], [@CR29]--[@CR32]\]. The difference in pharmacokinetic parameters between different studies may be due to different breeds or individual differences in pigs. In this study, after i.m. administration of DANO at a dose of 2.5 mg/kg body weight in pigs, the time to reach to maximum concentration (T~max~) was 0.97 ± 0.08 h, similar to 1 h as reported by Mann and Frame, but different from 0.64 h as described by Wang et al.*;* the peak drug concentration (C~max~) was 0.76 ± 0.08 μg/mL, higher than 0.45 ± 0.09 μg/mL, and was half of 1.5 μg/mL reported by Rottboll and Friis which dosing 5.0 mg/kg; the area under the curve by 24 h (AUC~24~) was 5.25 ± 1.35 h•μg/ml, higher than 3.34 ± 0.43 h•μg/ml as reported by Wang et al. \[[@CR10], [@CR31], [@CR33]\].

From a pharmacodynamic point of view, fluoroquinolones are considered concentration-dependent rather than time-dependent \[[@CR34]\]. The in vitro time kill test in our study demonstrated that DANO is also concentration dependent. Thus, the ratios of peak concentration or AUC with the MIC were reported as important determinants of the antibacterial effect of fluoroquinolones in vitro and the ratio of AUC~24~/MIC or C~max~/MIC were generally used for PK/PD modeling \[[@CR21], [@CR35]\].

The parameters C~max~/MIC and AUC~24~/MIC correlate well with therapeutic outcome. A correlation of these composite parameters to the efficacy of an antibacterial revealed that for fluoroquinolones an AUC~0--24~/MIC of ≥125 is predictive of favorable clinical outcome for Gram negative bacteria \[[@CR21]\]. The probability of DANO attaining an AUC: MIC ratio of at least 125 is 92.25%. Therefore, the CO~PD~ was defined at 0.03 μg/mL.

To the best of our knowledge, this is the first study to establish the ECV and CO~PD~ of DANO against *E.coli* by statistical method. The CO~PD~ (0.03 μg/mL) was much lower than the ECV (8 μg/mL) established in our study, implying that the lower CO~PD~ in our study may be due to the lower dose of drug administration to pigs, because previous studies concluded that the dose of drug administration may affect the PK-PD breakpoint \[[@CR36]--[@CR38]\]. This suggests that (i) more dosing regimens need to be designed in future investigation; (ii) Further studies are needed to illustrate the relationship between DANO non-WT values proposed in this study and its resistant molecular mechanisms.

Conclusions {#Sec10}
===========

Compared to the CO~PD~ of DANO against *E.coli* (0.03 μg/mL), the ECV for *E.coli* seemed reasonable to be used as the final breakpoint of DANO against *E.coli* in pigs. Therefore, the ECV (MIC≤8 μg/mL) was finally selected as the optimum DANO susceptibility breakpoint for swine *E.coli*, which could provide a criterion for DANO susceptibility testing and improve prudent use of DANO for protecting public health.

Methods {#Sec11}
=======

Isolates {#Sec12}
--------

The rectal/cloacal swabs collected on each farm from the pigs were pooled and tested as one analytical sample. Between July 2014 and March 2017, a total of 864 rectal/cloacal swabs of pig were collected in Heilongjiang (*n* = 297), Jilin (*n* = 151), Liaoning (*n* = 240), Henan (*n* = 97), Shandong (*n* = 30), Hubei (*n* = 20), and Yunnan (*n* = 29) provinces of China. In order to isolate *E. coli*, swabs were streaked out on MacConkey agar plates (Qingdao Hope Bio-Technology Co., Ltd., Qingdao, China) and incubated at 37 °C for 18 to 24 h. The putative *E. coli* isolates on MacConkey agar (bright pink with a dimple) per sample were transferred to eosin methylene blue agar (Qingdao Hope Bio-Technology Co., Ltd., Qingdao, China) for further purification and were incubated at 37 °C for 18 to 24 h. One colony with typical *E. coli* morphology was selected from each sample and identified by conventional biochemical methods according to 'Bergey's Manual of Determinative Bacteriology'. In addition, a total of 372 *E.coli* strains were respectively donated by National Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences (*n* = 108), Husbandry and Veterinary College, Jilin University (*n* = 112), and College of Animal Husbandry and Veterinary Science, Henan Agricultural University (*n* = 152). All of the bacterial isolates were confirmed by polymerase chain reaction (PCR) \[[@CR39]\].

Antibacterial susceptibility testing {#Sec13}
------------------------------------

Broth microdilution testing was performed in accordance with the guidelines in CLSI document M07-A9 \[[@CR40]\] at the following laboratories: Department of Microbiology, Department of Pharmacology and Toxicology, and Pharmacy Department in Northeast Agricultural University, Harbin, China. Pure powder of DANO (Qingdao Hope Bio-Technology Co., Ltd., Qingdao, China) was dissolved in ultrapure water to prepare stock solutions of 5120 μg/mL. Two-fold serial drug dilutions were prepared in broth (Qingdao Hope Bio-Technology Co., Ltd., Qingdao, China) to achieve the final concentration ranged from 0.008 to 128 μg/mL. Each well contains approximately 5 × 10^5^ CFU/mL *E.coli* and cultured in 96 well plates. Plates were incubated at 37 °C for 20 h. Quality control (QC) isolate *E.coli* ATCC 25922 was used on each day of testing by the participating laboratories, as recommended by CLSI \[[@CR40]\]. Only those results, for which the QC MICs were within the established reference range, were used in the study. The MIC is the lowest concentration of antimicrobial agent that completely inhibits growth of the organism in the microdilution wells as detected by the unaided eye. All MIC determinations were performed in triplicate.

Definitions {#Sec14}
-----------

The ECV (also known as the wild-type cutoff, or CO~WT~), defined as the highest susceptibility endpoint of the wild-type (WT) population MIC, has been shown to detect the emergence of in vitro resistance or to separate WT isolates (without known mechanisms of resistance) from non-WT isolates (with mechanisms of resistance and reduced susceptibilities to the antibacterial agent being evaluated) \[[@CR26], [@CR41]\]. ECVs are calculated by taking into account the MIC distribution, the modal MIC of each distribution, and the inherent variability of the test (usually within one doubling dilution) and should encompass ≥95% of isolates \[[@CR17]\].

Analysis {#Sec15}
--------

To analyze the MIC distributions, MICs were transformed into log~2~ values. The skewness and kurtosis of each MIC distribution were determined. Skewness quantifies the degree of symmetry of the distribution, whereas kurtosis quantifies the extent to which the shape of the data distribution matches the normal distribution. To confirm the presence of more than one MIC distribution, frequency distributions of MIC data were analyzed by nonlinear least squares regression analysis based on the following Cumulative Gaussian Counts equation:Z = (*X* − *Mean*)/*SD*, Y = N ∗ zdist(*z*), in which the Mean is the average of the original distribution, from which the frequency distribution was created; SD is the standard deviation of the original distribution (calculations were performed using Prism 6.0 software, San Diego, CA). Three parameters were estimated, the mean and SD (both log~2~), and the total number (N) in the presumed unimodal distribution. N was estimated rather than taken as a constant in the regression, because of the desire to fit the data to the distribution without assuming that N truly contained only wild-type isolates \[[@CR17], [@CR42]\].

In vitro time-kill studies {#Sec16}
--------------------------

In vitro time-kill studies were conducted in Mueller-Hinton broth with concentrations of DANO ranging from 1/4 to 32 times of the MICs for *E.coli* JLP95 (O~8~), which were tested separately. The initial inoculum sizes of the bacteria used to generate the time-kill profiles were approximately 10^6^ CFU/mL. 1.2 mL of co-culture was removed from each tube and then 200 μL of co-culture was continuously diluted with 1.8 mL Mueller-Hinton broth to measure the CFU at 0, 1, 2, 4, 6, 8, 12 and 24 h following inoculation.

Animals {#Sec17}
-------

Six 5-months-old healthy fragrance pigs weighing 14--16 kg were donated from Clinical Surgery Department's pig breeding farm of Northeast Agricultural University for free use. All animals were provided with a drug-free commercial diet to acclimatize for 1 week prior to the study. After the trial, all animals were returned to them for further feeding and used for subsequent laparoscopic trials. All experimental work was performed in accordance with the animal ethics guidelines approved by the animal care and ethics committee of Northeast Agricultural University (Heilongjiang Province PR China).

Pharmacokinetic study {#Sec18}
---------------------

DANO (purity \> 99%) was obtained from Zhejiang Guobang Pharmaceutical Company Limited, China. The pure reference standard of DANO was obtained from the Sigma-Aldrich (China).

DANO was intramuscularly injected at 2.5 mg DANO/kg body weight in each pig. Blood samples (5 mL) from the brachiocephalic vein were collected into EDTA dipotassium salt tubes at 0.15, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 and 72 h after injection. Plasma was separated by centrifugation at 3000 g for 10 min and stored at − 20 °C until analysis.

The method for the analysis of DANO concentration in plasma was modified from that described by \[[@CR43], [@CR44]\]. The HPLC system Waters 2695 was connected to a Waters 2475 fluorescence detector (λex =280 nm and λem = 450 nm) with a mixture of acetonitrile and aqueous solution (15:85, *v*/v) as the mobile phase. The aqueous solutions were prepared by dissolving potassium dihydrogenophosphate (0.020 M), phosphoric acid (0.006 M), and tetraethylammonium bromide (0.012 M) in water. The pH of the mobile phase was adjusted to 3.0 by addition of 2 N NaOH. The flow rate was set at 1.0 mL/min; A Waters C~18~ reverse phase column C~18~ (250 mm × 4.6 mm I.D.; particle size, 5 μm) was used to perform HPLC at 30 °C; and the injection volume was 10 μL.

Samples were thawed at room temperature, and 10 μL of 50 μg/mL ciprofloxacin (Sigma--Aldrich) was added to plasma (0.5 mL) as the internal standard. After adding 3 mL of acetonitrile, the mixed samples were shaken at 220 oscillations/min for 15 min and then centrifuged at 12000 g for 10 min. The organic layer was transferred into a sterilized tube and dried at 40 °C under nitrogen stream. The residue was dissolved in the mobile phase (0.5 mL), and 10 μL injected for HPLC analysis.

The limit of detection (LOD) was 0.005 μg/mL and the limit of quantification (LOQ) was 0.01 μg/mL in plasma, respectively. Standard curves were linear from 0.01 to 1.5 μg/mL in plasma (*R*^2^ = 0.9999). The inter-day variation for determination in plasma ranged from 0.18 to 1.50%. The recovery of DANO in plasma ranged from 85.80 ± 0.16% to 103.40 ± 4.89%.

Pharmacokinetic analysis {#Sec19}
------------------------

PK analysis was conducted by using WinNonlin v.5.2.1 (Pharsight Corporation, Mountain View, CA, USA). Mininmum Akaike Information Criteria Estimates (MAICE) was applied to determine the best fit of model for each pig \[[@CR45]\].

Monte Carlo analysis {#Sec20}
--------------------

A 10,000-subject Monte Carlo simulation was conducted for each drug at each of the following MIC: 0.008, 0.016, 0.03, 0.06, 0.03, 0.5, 1, 2, 4, 8, 16, 32, 64 and 128 μg/mL using ORACLE CRYSTAL BALL software (version 11.1; Oracle USA, Denver, CO, USA). Based on pharmacokinetic results of DANO in pigs in this study, a conservative PK/PD value (AUC~0--24~/MIC = 125) was selected to calculate the PTA \[[@CR21]\]. AUC~0--24~ was not measured for the fluoroquinolones, it was calculated as follows: AUC~0--24~ = Dose/V~ss~ × K~d~, where V~ss~ was the volume of distribution at steady state (L/kg) and K~d~ the elimination rate constant (h^− 1^) \[[@CR20]\]. AUC~0--24~ was assumed to be log-normally distributed, and the PK/PD indices were calculated for each simulated subject. The PTA was estimated at each MIC as the probability that at least the target level of the PK/PD index is achieved. The CO~PD~ was defined as the highest MIC at which the PTA was ≥90% \[[@CR46], [@CR47]\].
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